GlassScriptPhysician profile
Hailey Ott Davis
NPI 1104327667
$5,388.95
in general payments reported to CMS, 2019-2025
40 companies · $861 in 2025
The $861 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,142 · 2022: $1,526 · 2023: $1,018 · 2024: $842 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.52 | 2021-2025 | |
| Novo Nordisk INC | $438.76 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $433.02 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $311.58 | 2021-2025 | |
| Lilly USA, LLC | $281.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $206.24 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.39 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $169.64 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $163.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $161.65 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $149.62 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.86 | 2021-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.02 | 2022-2025 | Caplyta |
| Esperion Therapeutics, INC. | $108.49 | 2021-2025 | Nexletol |
| Dexcom, INC. | $106.73 | 2021-2025 | Dexcom G6 Transmitter |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.